GlobeNewswire·May 19, 2026, 8:00 AM ET

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Patrick Hensley, MD, & Daniel Joyce, MD, MS each received grants up to $50,000 from CG Oncology & SUO-CTC for the second annual NMIBC Research Fellowship.
The 2025 grant recipients, Taylor A. Goodstein, MD, & Saum B. Ghodoussipour, MD, presented their research at the SUO 2026 Annual Meeting at the AUA.
Hensley's research focuses on developing an AI-powered prognostic biomarker for intravesical cretostimogene in BCG-unresponsive NMIBC.
Joyce's research aims to provide individualized price transparency at the point of care for patients with BCG-unresponsive NMIBC.
Goodstein presented on spatial transcriptomic profiling of the tumor microenvironment in NMIBC patients treated with novel intravesical gene therapies.
Ghodoussipour presented on dynamic intra-tumor heterogeneity in non-muscle invasive bladder cancer.
Ambaw Bellete, President & COO of CG Oncology, stated the partnership reflects a shared commitment to advancing bladder cancer care through innovative research & collaboration.
SUO-CTC is a 501(c)(3) not-for-profit network of over 750 members from more than 350 clinical sites in the U.S. & Canada.
CG Oncology is a late-stage clinical biopharmaceutical company developing a potential backbone bladder-sparing therapeutic for bladder cancer patients.